At what age range is pheochromocytoma (adrenal gland tumor) typically diagnosed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pheochromocytoma Age Range

Pheochromocytoma is typically diagnosed at a median age of 40-50 years, with a reported range of 14-61 years in patients with neurofibromatosis type 1 (NF1). 1

Epidemiology and Age Distribution

  • The median age at diagnosis is 43 years (range 14-61 years) in patients with NF1 1
  • In the general population, pheochromocytoma can occur at any age with equal gender distribution 2
  • In a 50-year autopsy series, patient ages ranged from 40 hours to 92 years (mean 53 years) 3
  • A 20-year experience study found ages ranging from 17 to 74 (mean 43.2 years) 4

Age Differences by Genetic Predisposition

Different hereditary syndromes show varying age patterns for pheochromocytoma diagnosis:

  • NF1-associated pheochromocytomas: Diagnosed at older ages (mean 48 years) compared to other genetic syndromes (mean 30 years) 5
  • Bilateral pheochromocytomas: Typically diagnosed at a younger median age of 31 years (range 4-70) 6
  • SDHA-related pheochromocytomas: Median age of 43 years (range 17-81) 1
  • Hereditary syndromes: Manifest at younger ages than sporadic cases 2

Pediatric vs. Adult Presentation

  • Bilateral pheochromocytoma occurs in 37.5% of pediatric patients compared to only 7-8% of adults 6
  • Pediatric cases are more likely to be associated with genetic syndromes
  • In NF1 specifically, pheochromocytoma is rarely diagnosed through routine screening in children 5

Clinical Implications

  • Hypertension screening should begin at birth or diagnosis in NF1 patients 1
  • Pheochromocytoma should be considered in hypertensive NF1 patients who are over 30 years of age, pregnant, and/or have paroxysmal hypertension, hypertension-associated headache, palpitations, or sweating 1
  • The risk of malignancy is approximately 12% in NF1-associated pheochromocytomas 1
  • Approximately 22% of pheochromocytomas in NF1 patients are asymptomatic 1

Diagnostic Considerations by Age

  • In younger patients (<30 years), consider genetic testing as hereditary syndromes are more common
  • In middle-aged patients (40-50 years), maintain high clinical suspicion, especially with hypertension
  • In older patients, pheochromocytomas may be discovered incidentally on imaging for other conditions

Pitfalls and Caveats

  • Delayed diagnosis is common in NF1 patients due to lack of systematic screening 5
  • Pheochromocytoma can be lethal if undiagnosed, especially during surgery for unrelated conditions 3
  • In autopsy studies, 76% of pheochromocytomas were not suspected clinically before death 3
  • Hypertensive or hypotensive crisis during unrelated surgeries is a common cause of death in undiagnosed cases 3

The most recent guidelines recommend considering pheochromocytoma in the differential diagnosis for hypertension in NF1 patients, particularly those over 30 years of age, but routine biochemical screening in asymptomatic patients is not currently recommended 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.